New analysis of reverse trial reveals benefits of crt for more patients with heart failure

Dublin, march 2, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced new results from the landmark reverse trial, evaluating outcomes of cardiac resynchronization therapy (crt) for patients with mild heart failure (hf). this new analysis...
MDT Ratings Summary
MDT Quant Ranking